Advertisement

Pituitary

, Volume 22, Issue 6, pp 614–619 | Cite as

MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications

  • George KontogeorgosEmail author
  • Eleni Thodou
  • Mary Koutourousiou
  • Gregory Kaltsas
  • Andreas Seretis
Article

Abstract

Introduction

Temozolomide (TMZ) is currently considered as a rational therapeutic option for patients with progressively aggressive pituitary adenomas and carcinomas not responding to conventional therapies. Administration of TMZ results in clinical response and improvement in survival of many of these patients depending upon the expression of the DNA repair enzyme O-6 methylguanine DNA transferase (MGMT). Low or negative MGMT immunoreactivity predicts responsiveness to TMZ therapy. Therefore, MGMT serves as a criterion to select candidate patients anticipating response to treatment.

Materials and Methods

The MGMT expression was investigated in 25 pituitary adenomas with Ki-67 labeling index more that 3% and p53 expression, using various antigen retrieval protocols. After direct application of the antibody, only one adenoma yielded positive for MGMT. However, after pretreatment of tissue sections with antigen retrieval protocols, another 3 adenomas, initially negative turned to positive.

Conclusions

These findings could explain lack of response to TMZ treatment in patients with false negative MGMT immunohistochemistry. Evaluation of tumor samples for MGMT expression should carefully be carried-out using the optimum immunohistochemical protocol to obtain consistent and reliable results that help to identify patients that could respond to TMZ therapy.

Keywords

Antigen retrieval protocols Immunohistochemistry Ki-67 MGMT p53 Temozolomide 

Notes

Acknowledgements

No funding from official organization was received. We thank Mrs. Magda Pateraki and Soula Roumelioti for excellent technical support.

Compliance with ethical standards

Conflict of interest

The authors certify that they have NO involvement in any organization or entity with any financial interest in the context or materials discussed in this manuscript.

References

  1. 1.
    Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Diagnosis and management of pituitary carcinomas. J. Clin. Endocrinol. Metab. 90:3089–3099.  https://doi.org/10.1210/jc.2004-2231 CrossRefPubMedGoogle Scholar
  2. 2.
    Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J, Brue T (2012) Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin. Endocrinol. (Oxf.) 76:769–775.  https://doi.org/10.1111/j.1365-2265.2012.04381.x CrossRefGoogle Scholar
  3. 3.
    O’Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P, Stevens MFG (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A:940–942. Erratum in: Eur J Cancer 29A:1500 (1993)CrossRefGoogle Scholar
  4. 4.
    Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen SL (2002) A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro. Oncol. 4:261–267.  https://doi.org/10.1093/neuonc/4.4.261 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 20:1375–1382.  https://doi.org/10.1200/JCO.2002.20.5.1375 CrossRefPubMedGoogle Scholar
  6. 6.
    Syro LV, Rotondo F, Camargo M, Ortiz LD, Serna CA, Kovacs K (2018) Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions. Front. Endocrinol. (Lausanne) 9:1–14.  https://doi.org/10.3389/fendo.2018.00318 CrossRefGoogle Scholar
  7. 7.
    Long-term response of pituitary carcinoma to temozolomide (2006) Fadul, C.E., Kominsky, A.L., Meyer, L.P. Report of two cases. J. Neurosurg. 105:621.  https://doi.org/10.3171/jns.2006.105.4.621 CrossRefGoogle Scholar
  8. 8.
    Lim S, Shahinian H, Maya MM, Yong W, Heaney AP (2006) Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 7:518–520.  https://doi.org/10.1016/S1470-2045(06)70728-8 CrossRefPubMedGoogle Scholar
  9. 9.
    Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Horvath E, Rotondo F, Kovacs K (2009) Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones 8:303–306.  https://doi.org/10.14310/horm.2002.1247 CrossRefPubMedGoogle Scholar
  10. 10.
    Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE (2007) Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol 38:185–189. Erratum in: Hum Pathol 38:526 (2007)CrossRefGoogle Scholar
  11. 11.
    Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M (2009) Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur. J. Endocrinol. 161:631–637.  https://doi.org/10.1530/EJE-09-0389 CrossRefPubMedGoogle Scholar
  12. 12.
    Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Fadul CE (2008) MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 115:261–262.  https://doi.org/10.1007/s00401-007-0279-5 CrossRefPubMedGoogle Scholar
  13. 13.
    Syro LV, Ortiz LD, Scheithauer BW, Lloyd RV, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K, Horvath E (2011) Treatment of pituitary neoplasms with temozolomide: a review. Cancer 117:454–462.  https://doi.org/10.1002/cncr.25413 CrossRefPubMedGoogle Scholar
  14. 14.
    McCormack AI, Wass JA, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur. J. Clin. Invest. 41:1133–1148.  https://doi.org/10.1111/j.1365-2362.2011.02520.x CrossRefPubMedGoogle Scholar
  15. 15.
    Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K (2011) Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. Hormones (Athens) 10:162–167.  https://doi.org/10.14310/horm.2002.1307 CrossRefGoogle Scholar
  16. 16.
    McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA (2009) Low 06-methylguanine-DNA methyltransferase [p1] (mgmt) expression and response to temozolomide in aggressive pituitary tumors. Clin. Endocrinol. (Oxf.) 71:226–233.  https://doi.org/10.1111/j.1365-2265.2008.03487.x CrossRefGoogle Scholar
  17. 17.
    McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS (1998) Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Lab. Invest. 78:643–644PubMedGoogle Scholar
  18. 18.
    Lloyd RV, Kovacs K, Young WF Jr, Farell WE, Asa SL, Touillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E (2004) Pituitary Tumours: Introduction. In: DeLellis RA, Heitz P, Lloyd RV, Eng C (eds) WHO Classification of Tumours, Pathology and Genetics, Tumours of Endocrine Organs. IARC Press, Lyon, pp 10–13Google Scholar
  19. 19.
    Kontogeorgos G, Horvath E, Kovacs K, Coire C, Lloyd RV, Scheithauer BW, Smyth HS (2006) Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Acta Neuropathol. 111:46–52.  https://doi.org/10.1007/s00401-005-1111-8 CrossRefPubMedGoogle Scholar
  20. 20.
    Jaffrain-Rea ML (2014) From resistant to aggressive and malignant prolactinomas: a translational approach. J Endocr Disord 1:1–10Google Scholar
  21. 21.
    Osamura RY, Lopes MBS, Grossman A, Kontogeorgos G, Trouillas J (2017) Tumours of the pituitary gland. Introduction. In: Lloyd RV, Osamura RV, Klöppel G (eds) WHO classification of tumours of endocrine organs. IARC Press, LyonGoogle Scholar
  22. 22.
    Tanizaki Y, Jin L, Scheithauer BW, Kovacs K, Roncaroli F, Lloyd RV (2007) P53 gene mutations in pituitary carcinomas. Endocr. Pathol. 18:217–222.  https://doi.org/10.1007/s12022-007-9006-y CrossRefPubMedGoogle Scholar
  23. 23.
    Hasanov R, Aydoğan B, Kiremitçi S, Erden E, Güllü S (2019) The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas. Endocr. Pathol. 30:49–55.  https://doi.org/10.1007/s12022-018-9563-2 CrossRefPubMedGoogle Scholar
  24. 24.
    Zuhur SS, Tanik C, Karaman Ö, Velet S, Çil E, Öztürk FY, Özkayalar H, Müslüman AM, Altuntaş Y (2011) MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with labeling index and cytokeratin distribution pattern. Endocrine 40:222–227CrossRefGoogle Scholar
  25. 25.
    Almalki MH, Aljoaib NN, Alotaibi MJ, Aldabas BS, Wahedi TS, Ahmad MM, Alshahrani F (2017) Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. Hormones (Athens) 16:139–149.  https://doi.org/10.14310/horm.2002.1729 CrossRefGoogle Scholar
  26. 26.
    Micko ASG, Wöhrer A, Höftberger R, Vila G, Marosi C, Knosp E, Wolfsberger S (2017) MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas. Pituitary 20:643–653.  https://doi.org/10.1007/s11102-017-0829-3 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Asimakopoulou A, Tzanela M, Koletti A, Kontogeorgos G, Tsagarakis S (2014) Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide. Clin. Case Rep. 2:1–3.  https://doi.org/10.1002/ccr3.39 CrossRefPubMedGoogle Scholar
  28. 28.
    Bengtsson D, Schrøder HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, Krogh Rasmussen Å, van der Lely A, Petersson M, Johannsson G, Andersen M, Burman P (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J. Clin. Endocrinol. Metab. 100:1689–1698.  https://doi.org/10.1210/jc.2014-4350 CrossRefPubMedGoogle Scholar
  29. 29.
    Selek A, Cetinarslan B, Canturk Z (2019) The effect of somatostatin analogues on Ki-67 levels in GH-secreting adenomas. Growth Horm. IGF Res. 45:1–45.  https://doi.org/10.1016/j.ghir.2019.01.001 CrossRefPubMedGoogle Scholar
  30. 30.
    Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, Ishida Y, Takano K, Okinaga H, Matsuno A (2011) A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurg. 68:E1761–E1767.  https://doi.org/10.1227/NEU.0b013e318217161a CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • George Kontogeorgos
    • 1
    • 2
    Email author
  • Eleni Thodou
    • 3
  • Mary Koutourousiou
    • 4
  • Gregory Kaltsas
    • 1
  • Andreas Seretis
    • 5
    • 6
  1. 1.First Propaepeudic Department of Internal Medicine, Laikon HospitalNational and Kapodistrian University of AthensAthensGreece
  2. 2.Department of Pathology“G. Gennimatas” Athens General HospitalAthensGreece
  3. 3.Department of Pathology, School of MedicineUniversity of Thessaly, ViopolisLarissaGreece
  4. 4.Department of Neurological SurgeryUniversity of LouisvilleLouisvilleUSA
  5. 5.Neurosurgery DepartmentHenry Dunant HospitalAthensGreece
  6. 6.Department of Neurosurgery“G. Gennimatas” Athens General HospitalAthensGreece

Personalised recommendations